adapt
immun
respons
gener
varieti
effector
cell
molecul
cell
includ
cell
endow
variou
effector
function
capabl
secret
numer
cytokin
upon
cognat
interact
antigenpres
cell
molecul
includ
antibodi
recogn
specif
antigen
rais
diffus
whole
bodi
bloodstream
least
quantit
antibodi
major
effector
molecul
adapt
immun
antibodi
howev
biolog
activ
fab
portion
bind
antigen
except
rare
instanc
bind
antigen
littl
biolog
consequ
therapeut
antibodi
rais
receptor
li
et
al
ligand
elli
hicklin
prevent
ligandreceptor
interact
antireceptor
antibodi
mimic
agonist
et
al
recent
shown
howev
neutral
bacteri
toxin
joller
et
al
virus
malleri
et
al
antibodi
requir
fc
portion
bind
cellular
receptor
transport
immun
complex
intracellular
compart
degrad
antibodi
affect
antigen
inde
need
bind
antigen
fab
portion
also
interact
fc
portion
effector
system
includ
solubl
molecul
compon
enzymat
cascad
complement
cell
express
receptor
fc
portion
antibodi
fcr
mani
cell
myeloid
lineag
exert
varieti
biolog
activ
without
requir
prolifer
andor
differenti
equip
patternrecognit
receptor
enabl
interact
structur
born
secret
microorgan
myeloid
cell
effector
cell
innat
immun
unlik
lymphoid
cell
antigen
receptor
howev
express
fcr
bind
fcr
antibodi
provid
cell
bcell
receptorlik
immunoreceptor
bona
fide
immunolog
specif
antibodi
polyclon
natur
differ
specif
one
fcrexpress
cell
respond
specif
wide
repertoir
differ
antigen
bind
fcr
specif
antibodi
thu
enrol
effector
cell
innat
immun
adapt
immun
follow
innat
adapt
immun
use
effector
cell
fcr
inde
immunoreceptor
third
type
recogn
neither
nativ
antigen
bcell
receptor
bcr
associ
antigenderiv
peptid
major
histocompat
complex
molecul
tcell
receptor
tcr
antigenantibodi
complex
antibodi
function
extracellular
adapt
molecul
fab
fc
portion
bind
simultan
specif
epitop
antigen
fcr
cell
membran
respect
bcr
tcr
fcr
receptor
three
form
given
antigen
interact
deliv
signal
cell
immun
system
like
immunoreceptor
engag
specif
ligand
fcr
gener
intracellular
signal
modul
biolog
activ
cell
express
fcr
activ
wherea
other
inhibit
cellular
respons
fcr
iga
fcar
igg
fcgr
fcrn
ige
also
fcr
polymer
igm
iga
polyigr
mani
fcr
name
includ
roman
number
capit
letter
roman
number
refer
bind
affin
immunoglobulin
fcri
iv
highaffin
receptor
fcrii
iii
lowaffin
receptor
capit
letter
refer
gene
encod
fcr
eg
fcgriia
b
c
fcgriiia
b
encod
three
fcgrii
gene
two
fcgriii
gene
respect
human
human
fcr
often
refer
use
cd
nomenclatur
design
fcgriii
fcgrii
fcgri
fcari
figur
fcr
belong
immunoglobulin
superfamili
igsf
consist
immunoglobulinbind
polypeptid
made
extracellular
domain
secondari
structur
typic
igsf
molecul
hydrophob
transmembran
domain
nonstructur
intracytoplasm
domain
variabl
length
fcr
fcgriia
human
fcgriib
polyigr
mice
human
singlechain
receptor
fcr
multichain
receptor
compos
one
immunoglobulinbind
subunit
fcra
one
fcrg
two
fcrg
fcrb
common
subunit
fcrg
homodim
made
two
disulfid
bondlink
polypeptid
highli
conserv
mice
human
polypeptid
consist
extracellular
domain
transmembran
domain
intracytoplasm
domain
fcrg
share
multichain
receptor
fcrb
domain
polypetid
associ
multichain
fcr
express
mast
cell
basophil
fcrn
uniqu
mhc
class
ilik
molecul
bind
fc
portion
igg
instead
peptid
burmeist
et
al
multichain
fcr
must
associ
least
one
specif
subunit
order
express
need
fcrg
order
reach
plasma
membran
intracytoplasm
domain
inde
contain
retent
site
sequest
polypetid
endoplasm
reticulum
unless
associ
fcrg
letourneur
et
al
lobel
et
al
express
receptor
therefor
depend
tissu
distribut
fcrg
fcrgdefici
mice
activ
fcr
takai
et
al
mous
human
also
need
associ
fcrb
kinet
fcrb
express
mast
cell
basophil
speci
express
restrict
cell
mice
kinet
et
al
human
gounni
et
al
joseph
et
al
gounni
et
al
notic
mous
fcgriiia
express
requir
fcrg
fcrb
associ
subunit
mast
cell
kurosaki
et
al
fcrn
associ
fcrg
microglobulin
like
mhci
molecul
associ
mandatori
microglobulindefici
mice
express
fcrn
one
fcr
ctype
lectin
bind
howev
involv
interact
sugar
residu
fc
portion
ige
extracellular
lectin
domain
bind
affin
monomer
rel
low
howev
express
homotrimer
molecul
bind
ige
immun
complex
high
avid
antibodi
bind
fcr
variabl
affin
hulett
hogarth
bind
antibodi
fcr
revers
obey
mass
action
law
affin
fcr
character
affin
constant
ka
quotient
associ
constant
kon
divid
dissoci
constant
koff
figur
proport
highaffin
fcr
bind
monomer
immunoglobulin
absenc
antigen
occupi
vivo
wherea
lowaffin
fcr
bind
antibodi
multival
immun
complex
spite
high
concentr
circul
immunoglobulin
occupi
highaffin
fcr
howev
freed
bound
antibodi
dissoci
dissoci
constant
therefor
critic
determin
avail
highaffin
fcr
contrast
lowaffin
fcr
gener
avail
immun
complex
whenev
come
close
enough
human
figur
murin
human
receptor
fc
portion
ige
iga
igm
igg
figur
schemat
receptor
ige
iga
igg
express
mous
human
cell
hematopoiet
lineag
horizont
gray
bar
repres
plasma
membran
oval
symbol
repres
immunoglobulin
superfamili
domain
constitut
extracellular
domain
fc
receptor
green
box
repres
itam
red
box
repres
itim
affin
mous
human
fc
receptor
homolog
ige
iga
igg
subclass
affin
constant
determin
plasmon
reson
analysi
dierk
et
al
hibbert
et
al
diverg
immunoglobulin
g
subclass
activ
select
fc
receptor
bind
scienc
mancardi
da
iannascoli
b
hoo
england
p
bruhn
p
fcgammariv
mous
ige
receptor
resembl
macrophag
fcepsilonri
human
promot
igeinduc
lung
inflamm
j
clin
invest
bruhn
p
iannascoli
b
england
p
mancardi
da
fernandez
n
jorieux
highaffin
fcr
includ
iga
fcari
human
pigr
human
mice
ige
human
mice
igg
receptor
fcgri
fcrn
human
mice
fcgriv
mice
lowaffin
fcr
includ
ige
human
mice
igg
receptor
fcgrii
iii
human
mice
human
three
fcgrii
fcgriia
b
c
two
fcgriii
fcgriiia
b
wherea
mice
one
receptor
type
fcgriib
fcgriiia
divers
human
fcgrii
iii
increas
polymorph
select
residu
extracellular
domain
h
r
fcgriia
warmerdam
et
al
f
v
fcgriiia
n
n
v
fcgriiib
ori
et
al
altogeth
fcgr
describ
human
one
notic
fcr
isotypespecif
antibodi
sever
isotyp
bind
one
fcr
vice
versa
sever
fcr
bind
antibodi
one
isotyp
ka
mous
human
ige
kulczycki
metzger
metzger
human
mous
fcgr
human
mous
igg
subclass
respect
span
figur
bruhn
et
al
lowaffin
interact
describ
ige
igg
receptor
mous
ige
bind
mous
fcgriib
fcgriiia
ka
ae
takizawa
et
al
fcgriv
ka
ae
mancardi
et
al
notic
ka
especi
high
associ
constant
high
dissoci
constant
extrem
low
result
spite
extrem
low
concentr
plasma
ige
remain
bound
extend
period
time
readi
trigger
mast
cell
basophil
activ
allergen
come
anoth
point
keep
mind
even
though
affin
low
monomer
immunoglobulin
bind
lowaffin
fcr
bind
immun
complex
high
avid
affin
igg
bind
fcgr
depend
glycosyl
fc
portion
arnold
et
al
heavi
chain
contain
singl
coval
attach
biantennari
nglycan
highli
conserv
n
residu
domain
point
mutat
glycosyl
site
abrog
abil
igg
antibodi
bind
fcgr
engin
mutat
eg
n
q
aglycosyl
antibodi
therefor
longer
engag
fcgr
veri
et
al
use
blockingonli
molecul
aglycosyl
antibodi
specif
receptor
ligand
prevent
receptorligand
interact
without
engag
fcgr
notic
n
mutat
affect
bind
igg
fcrn
aglycosyl
antibodi
therefor
similarli
protect
degrad
glycosyl
antibodi
mutat
remov
fucos
residu
glycan
chain
found
enhanc
bind
modifi
antibodi
fcgriiia
irrespect
polymorph
affect
receptor
natsum
et
al
niwa
et
al
fcr
trigger
signal
bind
immunoglobulin
signal
aggreg
cell
membran
antibodi
plurival
antigen
maeyama
et
al
metzger
although
result
sequenc
event
lead
receptor
aggreg
differ
highaffin
lowaffin
fcr
monomer
antibodi
bind
first
highaffin
fcr
aggreg
plurival
antigen
bind
receptorbound
antibodi
antibodi
bind
first
antigen
gener
immun
complex
bind
therefor
simultan
aggreg
lowaffin
fcr
fcr
trigger
activ
signal
andor
inhibit
signal
natur
signal
primarili
depend
molecular
motif
contain
intracytoplasm
domain
fcr
receptor
subunit
fcr
associ
two
motif
identifi
immunoreceptor
tyrosinebas
activ
motif
itam
consist
two
yxxl
motif
separ
variabl
amino
acid
sequenc
reth
immunoreceptor
tyrosinebas
inhibit
motif
itim
consist
singl
yxxl
motif
preced
loos
conserv
often
hydrophob
residu
posit
vivier
motif
dileucin
intern
motif
found
mous
fcgriib
also
identifi
final
intracytoplasm
motif
fcrn
pigr
enabl
receptor
transcytos
igg
andor
iga
trough
epitheli
cell
activ
fcr
fcari
fcgri
fcgriia
fcgriic
fcgriiia
fcgriv
fcgriia
fcgriic
singlechain
receptor
possess
itam
fcari
fcgri
fcgriiia
fcgriv
associ
common
fcr
subunit
fcrg
fcrg
contain
two
itam
orloff
et
al
fcrb
contain
one
itam
upon
receptor
aggreg
itam
phosphoryl
src
famili
tyrosin
kinas
pribluda
et
al
initi
constitut
dynam
intracellular
signalosom
kent
et
al
activ
signal
domin
inhibit
signal
malbec
et
al
inhibitori
fcr
member
one
famili
lowaffin
receptor
igg
refer
fcgriib
ravetch
bolland
fcgriib
encod
singl
gene
gener
two
human
three
mice
isoform
membran
receptor
altern
splice
sequenc
encod
first
intracytoplasm
exon
hibb
et
al
lewi
et
al
ravetch
et
al
latour
et
al
inhibitori
properti
fcgriib
depend
itim
et
al
encod
third
intracytoplasm
exon
gene
present
intracytoplasm
domain
murin
human
fcgriib
isoform
unlik
activ
receptor
fcgriib
trigger
intracellular
signal
upon
aggreg
trigger
neg
signal
coaggreg
activ
receptor
immun
complex
et
al
condit
itim
fcgriib
phosphoryl
srcfamili
tyrosin
kinas
phosphoryl
itam
activ
receptor
malbec
et
al
phosphoryl
fcgriib
recruit
inhibitori
molecul
brought
signalosom
render
inhibit
signal
domin
activ
signal
lesourn
et
al
lesourn
aggreg
ident
fcr
homoaggreg
rare
situat
physiolog
even
cell
express
one
type
fcr
eg
fcgriib
murin
b
cell
fcgriiia
murin
nk
cell
immun
complex
coengag
fcr
immunoreceptor
bcr
b
cell
nkr
nk
cell
sever
fcr
coaggreg
igg
immun
complex
interact
cell
coexpress
sever
fcgr
cell
coexpress
fcr
sever
class
antibodi
heteroaggreg
ie
coaggreg
differ
type
fcr
coaggreg
fcr
immunoreceptor
actual
rule
rather
except
physiolog
condit
fcr
antibodi
class
immun
complex
contain
one
class
antibodi
cell
express
one
type
fcr
variou
combin
fcr
engag
cell
surfac
form
heteroaggreg
nonpredetermin
composit
fcr
thu
gener
varieti
signal
complex
depend
rel
proport
receptor
variou
type
coengag
immun
complex
activ
fcr
trigger
varieti
cellular
respons
includ
transcytosi
immunoglobulin
polar
cell
endocytosi
solubl
immun
complex
phagocytosi
particul
complex
exocytosi
preform
granular
mediat
includ
vasoact
amin
proteolyt
enzym
andor
cytotox
molecul
product
newli
form
lipidderiv
proinflammatori
mediat
secret
newli
transcrib
cytokin
chemokin
growth
factor
differ
immunoreceptor
induc
cell
activ
prolifer
fcr
induc
cell
activ
activ
fcr
induc
uniqu
biolog
respons
biolog
activ
induc
receptor
cell
natur
biolog
respons
trigger
antibodi
via
fcr
primarili
depend
cell
type
inde
determin
function
repertoir
cell
therefor
tissu
distribut
fcr
figur
fcr
essenti
express
myeloid
cell
type
express
lymphoid
cell
b
cell
nk
cell
nkt
cell
nonhematopoiet
cell
endotheli
cell
tumor
cell
also
express
fcr
fcrn
express
epitheli
cell
monocyt
macrophag
dendrit
cell
neutrophil
zhu
et
al
activ
fcr
express
myeloid
cell
lymphoid
cell
classic
antigen
receptor
ie
nk
cell
intraepitheli
gd
cell
intestin
woodward
jenkinson
deusch
et
al
express
matur
b
lymphocyt
lymphocyt
therefor
express
one
type
antigen
receptor
activ
fcr
interfer
lymphocyt
activ
trigger
clonal
express
antigen
receptor
interestingli
howev
activ
fcr
transient
express
preb
pret
cell
express
function
bcr
tcr
respect
low
level
fcgriiia
howev
report
express
subset
murin
cell
effici
trigger
antibodydepend
cellmedi
cytotox
dhanji
et
al
inhibitori
fcr
fcgriib
express
myeloid
cell
b
lymphocyt
nk
cell
cell
express
fcgriib
express
inhibitori
receptor
involv
cellcel
interact
long
fcgriib
restrict
tissu
distribut
human
mice
biolog
function
fcr
depend
function
repertoir
individu
fcrexpress
cell
cell
type
endocytos
phagocytos
even
less
transcytos
cell
expel
granul
contain
cytotox
mediat
cell
granul
contain
vasoact
proinflammatori
mediat
mani
cell
synthes
cytokin
chemokin
growth
factor
differ
type
fcr
therefor
involv
varieti
biolog
function
includ
pathogen
clearanc
toxin
neutral
antigen
captur
initi
antigen
present
cytotox
inflammatori
respons
biolog
function
howev
ensur
singl
cell
cell
popul
consist
mixtur
variou
cell
type
either
present
recruit
chemokin
andor
prolifer
respons
growth
factor
site
reaction
composit
popul
depend
time
locat
biolog
function
fcr
involv
therefor
result
biolog
properti
mani
cell
engag
reaction
given
place
given
time
pleiotrop
dynam
reason
role
play
fcr
poorli
understood
basi
vitro
investig
varieti
vivo
model
therefor
develop
investig
fcr
physiolog
patholog
establish
mice
model
antifcr
antibodi
simpli
inject
intraven
ideal
antifcr
antibodi
expect
block
bind
site
fcr
prevent
bind
antibodi
immun
complex
sometim
howev
mimic
immun
complex
trigger
biolog
respons
mani
case
possess
unalt
fc
portion
antifcr
antibodi
engag
fcr
express
neighbor
cell
wellmast
consequ
includ
deplet
cell
express
target
fcr
whole
panopli
fcrdefici
mice
gener
permit
major
progress
fcr
biolog
investig
role
individu
fcr
use
ko
mice
reveal
uniqu
properti
fcr
also
reveal
function
redund
mani
fcr
fcrgdefici
mice
lack
activ
fcr
unravel
essenti
role
play
receptor
normal
patholog
antibodydepend
process
likewis
fcgriibdefici
mice
permit
identifi
mani
biolog
respons
neg
regul
receptor
neither
fcrgdefici
mice
fcgriibdefici
mice
howev
devoid
problem
due
compensatori
reaction
occur
develop
longterm
consequ
regul
loss
celltypespecif
induc
fcr
defici
base
use
crelox
system
develop
overcom
problem
mice
inde
invalu
studi
mous
biolog
enabl
one
draw
conclus
human
biolog
inde
mous
human
fcr
ident
mani
differ
tissu
distribut
sever
team
therefor
gener
human
transgen
mice
express
human
fcr
transgen
human
fcr
place
control
promot
hope
result
mice
express
fcr
tissu
distribut
human
transgen
mice
made
normal
mice
human
fcr
express
addit
endogen
murin
fcr
make
difficult
determin
respect
role
human
murin
fcr
transgen
mice
made
fcrdefici
mice
inform
unless
use
assess
effect
passiv
administ
human
antibodi
shortterm
assay
one
limit
mous
immunoglobulin
bind
ident
human
murin
fcr
bypass
difficulti
mice
construct
use
mice
locu
contain
c
h
gene
replac
whole
part
human
homolog
base
variou
mous
model
whole
set
data
accumul
role
play
fcr
health
diseas
fcr
critic
molecul
immun
system
mediat
biolog
activ
antibodi
ie
main
effector
socal
humor
immun
ubiquit
express
antibodi
circul
bloodstream
fcr
involv
wide
array
biolog
activ
physiolog
patholog
activ
essenti
investig
immun
anim
like
concur
homeostasi
physiolog
readili
access
investig
condit
thu
thoroughli
document
patholog
condit
fcr
critic
protect
immun
respons
pathogen
fcr
also
contribut
gener
patholog
process
trigger
releas
potenti
harmfulin
case
lifethreateninginflammatori
mediat
induc
destruct
cytotox
mechan
therefor
activ
properti
tightli
control
regulatori
mechan
consequ
immun
respons
normal
nonpathogen
reason
fcr
either
valuabl
tool
exquisit
target
passiv
immunotherapi
although
individu
lack
fcgri
fcgriia
fcgriiia
fcari
display
obviou
phenotyp
ceuppen
et
al
de
haa
et
al
import
physiolog
role
could
assign
fcr
fcr
control
amount
transport
immunoglobulin
other
critic
control
adapt
immun
respons
fcrndefici
mice
abnorm
low
serum
igg
israel
et
al
gheti
et
al
spite
normal
bcell
function
roopenian
et
al
reason
fcrn
protect
igg
antibodi
degrad
raghavan
et
al
huber
et
al
junghan
anderson
phenomenon
explain
halflif
igg
day
spiegelberg
fishkin
wherea
igm
iga
ige
day
respect
butler
invers
keep
plasma
concentr
ige
low
mice
high
ige
level
downregul
product
ige
yu
et
al
transcytosi
immunoglobulin
across
polar
cell
induc
sever
fcr
fcrn
contribut
passag
igg
tissu
blood
fcrn
express
human
proxim
kidney
cell
haymann
et
al
kobayashi
et
al
may
lower
elimin
igg
urin
reabsorb
filter
igg
lobo
et
al
also
suggest
fcrn
express
mammari
gland
recycl
colostr
igg
blood
cianga
et
al
mous
hepatocyt
borvak
et
al
telleman
junghan
human
alveolar
epitheli
cell
spiekermann
et
al
also
express
fcrn
fccoupl
protein
administ
airway
reach
blood
fcdepend
manner
low
et
al
bitonti
et
al
express
intestin
fcrn
found
deliv
igg
lumen
absorb
immun
complex
back
et
al
yoshida
et
al
pregnanc
transplacent
transfer
matern
immunoglobulin
fetu
confer
protect
fetu
whose
humor
respons
ineffici
palmeira
et
al
igg
immunoglobulin
class
cross
human
placenta
ensur
humor
protect
kim
et
al
fcrn
express
syncytiotrophoblast
fetal
intestin
shah
et
al
simist
mandatori
matern
igg
transfer
fetus
simist
ree
fcgriib
express
human
placent
endothelium
believ
contribut
igg
transport
recent
studi
fcgriibdefici
mice
howev
demonstr
fcgriib
dispens
mohanti
et
al
altogeth
report
underlin
uniqu
role
fcrn
igg
transport
iga
lesser
extent
igm
transcytos
pigr
receptor
mandatori
iga
secret
pigrdefici
mice
detect
iga
mucos
compart
johansen
et
al
ig
transport
pigr
remark
effici
especi
mammari
gland
matur
breast
milk
especi
rich
iga
igm
brandtzaeg
concentr
iga
human
milk
reach
g
l
kuo
et
al
iga
antibodi
thought
protect
intestin
mucosa
brandtzaeg
et
al
final
shown
transport
ige
igeimmun
complex
enterocyt
yang
et
al
also
select
transport
ige
colostrum
hine
et
al
antibodi
function
potent
adjuv
properti
depend
fcr
express
differ
cell
type
involv
differ
condit
differ
mechan
uptak
antigenigg
antibodi
complex
dendrit
cell
fcr
may
inde
contribut
cross
present
machi
et
al
mhc
class
ii
present
heyman
antigen
cell
engag
activ
fcgr
dendrit
cell
antigenantibodi
complex
shown
induc
activ
matur
dendrit
cell
regnault
et
al
promot
antigenspecif
respons
vivo
schuurhui
et
al
inde
dendrit
cell
lack
activ
fcr
unabl
trigger
mhc
class
class
ii
present
thu
initi
effici
antitumor
respons
desai
et
al
requir
specif
igg
antibodi
produc
igginduc
enhanc
immun
respons
like
promot
effici
memori
respons
rather
primari
respons
enhanc
effect
igg
antibodi
antigen
present
control
inhibitori
receptor
coengag
fcgriib
activ
fcr
inde
shown
suppress
immun
complexinduc
dendrit
cell
matur
dampen
antigen
present
kalergi
ravetch
therefor
thought
physiolog
condit
fcgriib
interfer
process
antigen
intern
immun
complex
via
activ
fcr
inde
shown
crossprim
self
ag
dendrit
cell
neg
regul
fcgriib
fcgriib
may
thu
import
role
mainten
peripher
tcell
toler
desai
et
al
notic
fcgriib
express
dendrit
cell
inhibit
antigen
present
fcgriib
express
follicular
dendrit
cell
promot
tindepend
bcell
activ
antigen
display
repetit
epitop
mond
et
al
follicular
dendrit
cell
trap
immun
complex
secondari
lymphoid
tissu
complex
period
arrang
like
epitop
tindepend
antigen
szakal
et
al
fcgriib
express
follicular
dendrit
cell
engag
fc
portion
antibodi
present
immun
complex
prevent
bind
b
cell
fcgriib
el
shikh
et
al
absenc
fcgriib
follicular
dendrit
cell
immun
complex
coengag
bcr
fcgriib
b
cell
inhibit
bcell
activ
antigen
immun
complex
bound
follicular
dendrit
cell
thu
far
potent
induc
antibodi
respons
free
antigen
phenomenon
demonstr
vitro
tew
et
al
vivo
wu
et
al
ige
antibodi
also
found
potent
adjuv
adapt
immun
respons
igeinduc
enhanc
abrog
mice
ige
immun
complex
inde
effici
present
antigen
cell
interact
express
b
cell
getahun
et
al
igeinduc
enhanc
affect
class
antibodi
westman
et
al
although
express
type
cell
b
cell
follicular
dendrit
cell
involv
explain
enhanc
antigen
specif
b
cell
possess
specif
bcr
receiv
cognat
cell
help
lead
antibodi
product
hjelm
et
al
unlik
immun
respons
solubl
antigen
immun
respons
particul
antigen
suppress
minut
amount
igg
antibodi
suppress
thu
affect
ongo
antierythrocyt
immun
respons
whether
primari
secondari
observ
provid
rational
inject
rh
mother
given
birth
rh
babi
antirhd
antibodi
mean
prevent
hemolyt
diseas
newborn
unexpectedli
fcgriibdepend
neg
regul
appear
account
feedback
regul
antibodi
regul
inde
unalt
fcgriibdefici
mice
heyman
et
al
also
mice
lack
fcgr
unlik
respons
particul
antigen
respons
solubl
antigen
markedli
enhanc
igg
antibodi
hjelm
et
al
protect
role
antibodi
well
known
infect
best
evid
provid
vaccin
antibodi
inde
respons
protect
effect
overwhelm
major
vaccin
contribut
fcr
howev
poorli
known
neutral
antibodi
inde
thought
account
protect
case
mechan
investig
specif
antibodi
produc
detect
bloodstream
human
mice
follow
bacteri
viral
infect
jancar
sanchez
crespo
antivir
antibodi
may
profoundli
affect
viral
infect
fcrdepend
mechan
recent
report
neutral
effect
antibodi
requir
bind
depend
interact
fc
portion
antibodi
uniqu
intracellular
fcr
name
trim
malleri
et
al
classic
activ
fcr
need
clear
influenza
viru
huber
et
al
notic
engag
activ
fcgr
unrel
immun
complex
found
inhibit
replic
primari
human
macrophag
david
et
al
antibodi
also
protect
bacteri
infect
hangartn
et
al
well
known
neutral
bacteri
toxin
surprisingli
neutral
bacillu
anthaci
toxin
found
depend
engag
fcr
abboud
et
al
fcr
also
involv
clearanc
invad
bacteria
phagocytosi
microb
legionella
joller
et
al
salmonella
tobar
et
al
toxoplasma
joiner
et
al
enhanc
presenc
specif
antibodi
fcr
interestingli
presenc
specif
iga
suffici
decreas
bacteri
load
suggest
immunoglobulin
class
igg
contribut
antibacteri
immun
william
et
al
fcrgdefici
mice
fail
control
leishmania
major
padigel
farrel
mycobacterium
tuberculosi
maglion
et
al
infect
convers
fcgriibdefici
mice
display
enhanc
resist
bacteria
among
activ
fcr
account
antimicrobi
activ
poorli
investig
fcgriiia
seem
play
predomin
role
thoma
buxbaum
fcgridefici
mice
howev
suscept
bordello
pertussi
infect
patient
febril
infect
display
elev
level
fcgri
fcgrii
especi
neutrophil
leino
et
al
final
recent
evid
support
involv
fcrdepend
mechan
parasit
infect
fcgriiib
polymorph
associ
clinic
malaria
ghana
adu
et
al
fcgri
report
control
plasmodium
infect
mous
model
mcintosh
et
al
instanc
rather
protect
antibodi
favor
aggrav
infect
antibodi
viral
protein
name
spike
enabl
sever
acut
respiratori
syndrom
coronaviru
enter
infect
epitheli
cell
prevent
cell
infect
antispik
antibodi
howev
recent
found
enhanc
infect
human
immun
cell
interact
fcgr
jaum
et
al
likewis
antibodi
may
enhanc
hiv
infect
inde
fcr
bind
antibodi
complex
protein
hiv
fust
fcr
aggreg
ensu
enabl
intern
antibodyhiv
complex
consequ
monocyt
infect
jouault
et
al
case
fcr
facilit
bacteri
infect
bacteria
inde
interact
directli
fcr
express
immun
cell
escherichia
coli
express
outer
membran
protein
ompa
bind
fcgri
prevent
phosphoryl
fcrg
subunit
mittal
et
al
e
coli
bound
ompa
fcgriexpress
macrophag
bacteria
enter
cell
transfer
experi
demonstr
macrophag
fcgri
mandatori
e
coli
infect
mening
symptom
fcgridefici
mice
inde
resist
e
coli
infect
increas
suscept
spontan
tumor
format
report
neither
fcrgdefici
activ
fcgrdefici
mice
tumor
howev
found
alter
fcr
express
possibl
thu
escap
immun
surveil
myelomainduc
downregul
activ
fcr
immun
cell
may
decreas
fcrdepend
antitumor
mechan
studi
report
upregul
fcgriib
lymphoma
cell
callanan
et
al
ectop
express
fcgriib
also
observ
tumor
cell
melanoma
cell
cassard
et
al
role
fcgriib
express
tumor
cell
known
well
establish
initi
allerg
reaction
receptorbound
ige
aggreg
plurival
allergen
mast
cell
basophil
mice
inde
fail
develop
igeinduc
passiv
system
anaphylaxi
psa
dombrowicz
et
al
passiv
cutan
anaphylaxi
pca
dombrowicz
et
al
mast
cell
critic
reaction
wershil
et
al
arimura
et
al
human
also
trigger
pca
fungleung
et
al
psa
dombrowicz
et
al
induc
human
ige
transgen
mice
express
eosinophil
tanaka
et
al
monocyt
maurer
et
al
alveolar
macrophag
ochiai
et
al
neutrophil
gounni
et
al
platelet
joseph
et
al
patient
high
ige
level
may
increas
allerg
symptom
although
known
sinc
igg
antibodi
especi
subclass
recent
rediscov
induc
psa
mous
model
miyajima
et
al
fcgriiia
activ
receptor
bind
receptor
demonstr
critic
use
fcgriiiadefici
mice
recent
studi
confirm
predomin
role
fcgriiia
anaphylaxi
fcgriv
howev
receptor
bind
recent
demonstr
contribut
activ
system
anaphylaxi
asa
togeth
fcgriiia
express
fcgriv
restrict
neutrophil
monocytesmacrophag
cell
type
found
contribut
system
anaphylaxi
strait
et
al
fcgriiia
howev
play
predomin
role
anaphylaxi
bind
also
antibodi
produc
much
higher
amount
express
mast
cell
basophil
fcgriiiaexpress
mast
cell
inde
mandatori
pca
hazenbo
et
al
one
studi
report
involv
fcgri
pca
howev
convinc
evid
major
role
fcgri
anaphylaxi
fcgriib
inhibit
pca
fcgriibdefici
mice
inde
display
markedli
increas
anaphylaxi
compar
wild
type
mice
takai
et
al
ujik
et
al
unlik
wellestablish
role
fcgr
experiment
anaphylaxi
role
fcgr
human
allergi
far
clear
recent
studi
nevertheless
demonstr
abil
human
fcgr
induc
allerg
reaction
use
transgen
mice
mancardi
et
al
human
fcgri
fcgriia
trigger
igginduc
psa
asa
fcgriia
express
mast
cell
also
respons
igginduc
pca
mous
defici
endogen
fcgr
transgen
human
fcgr
underw
anaphylaxi
follow
inject
aggreg
human
igg
smith
et
al
final
transfer
human
neutrophil
express
fcgriia
could
restor
anaphylaxi
resist
mice
suggest
human
fcgriia
also
human
neutrophil
trigger
igginduc
anaphylaxi
recent
found
igg
receptor
express
human
basophil
function
inhibitor
cell
activ
consequ
basophil
fail
activ
igg
immun
complex
igg
immun
complex
coengag
fcgr
basophil
inhibit
igedepend
basophil
activ
normal
donor
test
cassard
et
al
fcr
involv
antibodydepend
autoimmun
diseas
although
iga
ige
account
autoimmun
disord
nephropathi
coppo
et
al
bullou
pemphigoid
fairley
et
al
respect
although
igminduc
complementdepend
autoimmun
report
pathogen
autoantibodi
igg
class
fcgriibdefici
mice
spontan
develop
autoimmun
diseas
age
antidna
antichromatin
antibodi
found
mice
usual
succumb
month
age
due
fatal
autoimmun
glomerulonephr
ravetch
bolland
thu
fcgriib
seem
contribut
peripher
toler
bolland
ravetch
invers
activ
fcgr
contribut
develop
autoimmun
diseas
antiplateletinduc
idiopath
thrombocytopen
purpura
itp
prevent
fcrgdefici
mice
fossatijimack
et
al
fcgri
fcgriiia
fossatijimack
et
al
fcgriv
demonstr
contribut
platelet
deplet
use
fcrdefici
mice
receptor
suffici
induc
itp
suggest
redund
role
activ
fcgr
involv
fcgri
fcgriiia
fcgriv
also
report
system
lupu
erythematosu
sle
sere
et
al
experiment
hemolyt
anemia
meyer
et
al
sy
et
al
glomerulonephr
fujii
et
al
arthriti
bruhn
et
al
ioanfacsinay
et
al
mancardi
et
al
role
fcgri
arthriti
howev
controversi
blockad
fcgriiia
fcgriv
wild
type
mice
abolish
symptom
neutrophil
infiltr
joint
role
human
fcr
experiment
autoimmun
diseas
investig
transgen
mice
human
fcgriia
induc
itp
reilli
et
al
arthriti
pietersz
et
al
express
human
fcgri
mice
lack
activ
fcr
restor
arthriti
symptom
mancardi
et
al
submit
contribut
iga
human
fcari
glomerulonephr
well
establish
launay
et
al
fcr
seem
play
redund
role
antibodyinduc
autoimmun
fcr
express
mous
monocytesmacrophag
neutrophil
two
cell
type
respons
phagocytosi
opson
particl
macrophag
neutrophil
mandatori
autoimmun
diseas
arthriti
solomon
et
al
wipk
allen
lung
inflamm
skokowa
et
al
thrombocytopenia
tan
et
al
slight
differ
observ
autoimmun
reaction
induc
differ
subclass
mous
igg
autoimmun
hemolyt
anemia
aha
depend
fcgriiia
fcgriv
wherea
aha
depend
fcgriiia
fcgriv
fcgri
baudino
et
al
aha
induc
low
dose
autoantibodi
seem
induc
fcgriiia
altogeth
data
demonstr
crucial
role
everi
fcr
autoantibodyinduc
reaction
role
fcr
human
autoimmun
highlight
success
use
ivig
specif
block
antibodi
see
fcr
may
also
involv
autoimmun
disord
central
nervou
system
cn
okun
et
al
antimyelin
antibodi
found
multipl
sclerosi
antidopaminerg
neuron
antibodi
parkinson
diseas
mcraedegueurc
et
al
antibodi
thought
induc
inflamm
activ
fcrexpress
phagocyt
cell
mani
cell
cn
express
fcr
immun
cell
recruit
bloodstream
brain
disord
fcrgdefici
mice
display
decreas
phagocytosi
model
alzheim
diseas
da
et
al
less
lesion
elimin
tyrosin
hydroxylaseposit
cell
model
parkinson
diseas
et
al
reduc
mortal
model
ischem
stroke
komin
kobayashi
et
al
interestingli
fcgriibdefici
mice
enhanc
diseas
suscept
wherea
mice
lack
igg
activ
fcr
protect
mous
model
multipl
sclerosi
robbieryan
et
al
furthermor
reconstitut
resist
mice
fcgriiiaexpress
bone
marrowderiv
mast
cell
restor
symptom
conclus
mechan
autoantibodi
product
deposit
cn
disord
poorli
document
pathogen
antibodi
seem
larg
mediat
fcr
therapeut
approach
develop
base
abil
fcr
induc
phagocytosi
andor
antibodydepend
cellmedi
cytotox
adcc
aim
one
use
antibodi
direct
antigen
express
target
cell
opson
cell
interact
fcrexpress
cell
phagocytos
kill
adcc
therapeut
antibodi
use
cancer
bacteri
infect
autoimmun
disord
thu
passiv
administr
specif
igg
antibodi
protect
wild
type
mice
fcrgdefici
mice
infect
cryptococcu
neoforman
yuan
et
al
likewis
inject
antitumor
antibodi
lead
signific
reduct
tumor
mass
wt
mice
fcrgdefici
mice
fcgriiia
seem
play
predomin
role
antitumor
activ
fcgri
bevaart
et
al
fcgriv
howev
report
particip
reaction
notic
enhanc
reject
observ
fcgriibdefici
mice
human
fcgri
trigger
tumor
clearanc
transgen
mice
inject
human
antibodi
mancardi
et
al
blood
press
suggest
human
fcr
may
respons
antitumor
effect
therapeut
antibodi
sever
monoclon
antibodi
rituximab
trastuzumab
use
clinic
exert
therapeut
effect
fcr
rituximab
human
antibodi
approv
bcell
malign
inde
kill
transform
b
cell
manch
et
al
antitumor
activ
partial
mediat
fcr
rituximab
also
use
treat
rheumatoid
arthriti
patient
inde
elimin
autoimmun
b
cell
respons
product
pathogen
antibodi
shaw
et
al
edward
et
al
trastuzumab
antibodi
bind
breast
ovari
lung
cancer
cell
addit
block
cell
prolifer
prevent
receptor
dimer
yake
et
al
trastuzumab
also
induc
tumor
destruct
engag
fcr
fc
portion
clyne
et
al
antibodi
target
molecul
express
dendrit
cell
enhanc
antigen
present
therefor
tcell
depend
cytotox
tumor
cell
effect
report
involv
fcgriib
li
ravetch
efficaci
therapeut
antibodi
markedli
improv
increas
halflif
enhanc
affin
activ
fcr
decreas
affin
inhibitori
fcr
mutat
describ
enhanc
affin
therapeut
antibodi
fcrn
ward
ober
consequ
plasma
concentr
mutant
antibodi
increas
dallacqua
et
al
mutat
remov
fucos
residu
glycan
chain
fc
portion
antibodi
enhanc
affin
antibodi
human
fcgriiia
natsum
et
al
niwa
et
al
also
mous
fcgriv
one
clinic
trial
use
block
antifcgri
antibodi
treatment
idiopath
thrombocytopenia
antibodi
markedli
reduc
symptom
ericson
et
al
diseas
howev
abolish
suggest
fcr
fcgri
particip
pathogenesi
support
conclus
administr
antifcgriiia
antibodi
patient
therapeut
effect
clarkson
et
al
antibodi
function
blockingonli
antibodi
engin
n
q
point
mutat
mutat
prevent
glycosyl
antibodi
longer
engag
fcr
veri
et
al
aglycosyl
antibodi
either
specif
receptor
ligand
prevent
receptorsligand
interact
without
engag
fcr
intraven
immunoglobulin
ivig
consist
pool
igg
thousand
normal
donor
initi
conceiv
substitut
treatment
immunodefici
ivig
prove
effici
sever
patholog
condit
high
dose
ivig
inde
antiinflammatori
effect
becam
effici
treatment
sever
autoimmun
diseas
arthriti
itp
sle
bayari
et
al
effect
reproduc
ivig
fc
fragment
suggest
fcr
contribut
antiinflammatori
effect
ivig
anthoni
ravetch
therapeut
effect
ivig
enhanc
increas
concentr
sialic
acidrich
immunoglobulin
kaneko
et
al
mechan
underli
phenomenon
remain
unclear
diverg
hypothes
point
role
fcrn
activ
fcr
fcgriib
satur
block
upregul
respect
ivig
nimmerjahn
ravetch
therapeut
approach
allerg
diseas
mainli
focu
ige
andor
recombin
solubl
propos
amelior
allerg
symptom
gavin
et
al
recombin
molecul
expect
compet
endogen
ige
inde
inject
suffici
amount
may
decreas
ige
anoth
strategi
target
membran
proapoptot
molecul
induc
intern
complex
subsequ
kill
cell
belostotski
lorberboumgalski
omalizumab
human
monoclon
antibodi
direct
site
ige
develop
prevent
mast
cell
basophil
sensit
ige
omalizumab
howev
found
form
igeantiig
complex
rapidli
degrad
serum
ige
becom
undetect
djukanov
et
al
halflif
markedli
reduc
absenc
receptorbound
ige
basophil
mast
cell
reduc
express
spite
side
effect
vichyanond
omalizumab
effici
reduc
sever
symptom
allerg
diseas
asthma
buss
et
al
season
rhiniti
casal
et
al
chronic
urticaria
kaplan
et
al
experiment
therapeut
approach
develop
aim
coengag
ige
mast
cell
basophil
fcgrii
zhu
et
al
tam
et
al
fcgriib
inde
found
exert
domin
inhibitori
effect
fcgriia
human
basophil
cassard
et
al
final
antibodydepend
effector
function
immun
respons
depend
varieti
paramet
depend
avail
natur
antibodi
antibodi
present
rel
high
concentr
blood
hematopoiet
organ
rel
low
concentr
peripher
tissu
skin
local
concentr
antibodi
howev
high
ige
nasal
polyp
contain
igesecret
plasma
cell
takhar
et
al
isotop
composit
immun
complex
given
time
given
place
also
critic
depend
fcr
express
given
cell
given
time
highaffin
fcr
may
occupi
least
part
antibodi
differ
specif
fcr
induc
other
constitut
express
upand
downregul
cytokin
rel
express
fcr
especi
activ
vs
inhibitori
fcr
myeloid
cell
present
site
critic
paramet
depend
tissu
distribut
fcr
fcrexpress
cell
differ
function
repertoir
may
present
low
number
defin
proport
initi
respons
recruit
high
number
differ
proport
inflammatori
infiltr
case
fcr
central
antibodydepend
reaction
therefor
potent
potenti
tool
privileg
target
immunotherapi
see
also
antigen
present
evolut
immun
system
natur
killer
cell
platelet
structur
function
immunoglobulin
v
j
recombin
somat
hypermut
class
switch
recombin
white
blood
cell
lymphoid
tissu
